An increase in apoptotic events may underlie neuropathology in schizophrenia. By data-mining approaches, we identified significant expression changes in death receptor signaling pathways in the dorsolateral prefrontal cortex (DLPFC) of patients with schizophrenia, particularly implicating the Tumor Necrosis Factor Superfamily member 6 (FAS) receptor and the Tumor Necrosis Factor [ligand] Superfamily member 13 (TNFSF13) in schizophrenia. We sought to confirm and replicate in an independent tissue collection the noted mRNA changes with quantitative real-time RT-PCR. To test for regional and diagnostic specificity, tissue from orbital frontal cortex (OFC) was examined and a bipolar disorder group included. In schizophrenia, we confirmed and replicated significantly increased expression of TNFSF13 mRNA in the DLPFC. Also, a significantly larger proportion of subjects in the schizophrenia group had elevated FAS receptor expression in the DLPFC relative to unaffected controls. These changes were not observed in the bipolar disorder group. In the OFC, there were no significant differences in TNFSF13 or FAS receptor mRNA expression. Decreases in BH3 interacting domain death agonist (BID) mRNA transcript levels were found in the schizophrenia and bipolar disorder groups affecting both the DLPFC and the OFC. We tested if TNFSF13 mRNA expression correlated with neuronal mRNAs in the DLPFC, and found significant negative correlations with interneuron markers, parvalbumin and somatostatin, and a positive correlation with PPP1R9B (spinophilin), but not DLG4 (PSD-95). The expression of TNFSF13 mRNA in DLPFC correlated negatively with tissue pH, but decreasing pH in cultured cells did not cause increased TNFSF13 mRNA nor did exogenous TNFSF13 decrease pH. We concluded that increased TNFSF13 expression may be one of several cell-death cytokine abnormalities that contribute to the observed brain pathology in schizophrenia, and while increased TNFSF13 may be associated with lower brain pH, the change is not necessarily causally related to brain pH.
References
[1]
Jia P, Wang L, Meltzer HY, Zhongming Z (2010) Common variants conferring risk of schizophrenia: A pathway analysis of GWAS data. Schizophr Res 122: 38–42.
[2]
Kim S, Webster MJ (2010) Correlation analysis between genome-wide expression profiles and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorder. Mol Psychiatry 15: 326–336.
[3]
Kim S, Webster MJ (2010) The Stanley Neuropathology Consortium integrative database: A novel, web-based tool for exploring neuropathological markers in psychiatric disorders and the biological processes associated with abnormalities of those markers. Neuropsychopharmacology 35: 473–482.
[4]
Kim S, Webster MJ (2011) Integrative genome-wide association analysis of cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders. Mol Psychiatry 16: 452–461.
[5]
Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH (2004) Apoptotic proteins in the temporal cortex in schizophrenia: High Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry 161: 109–115.
[6]
Gottfried Y, Rotem A, Klein E, Larisch S (2007) The pro-apoptotic ARTS/Sept4 protein is significantly reduced in postmortem brains from schizophrenia patients. Schizophr Res 96: 257–266.
[7]
Benes FM, Walsh L, Bhattacharyya S, Sheth A, Berretta S (2003) DNA fragmentation decreased in schizophrenia but not bipolar disorder. Arch Gen Psychiatry 60: 359–364.
[8]
Pakkenberg B (1993) Total nerve cell number in neocortex in chronic schizophrenics and controls estimated using optical dissectors. Biol Psychiatry 34: 768–772.
[9]
Thune JJ, Uylings HBM, Pakkenberg B (2001) No deficit in total number of neurons in the prefrontal cortex in schizophrenics. J Psychiatric Res 35: 15–21.
[10]
Selemon LD, Rajkowska G, Goldman-Rakic PS (1995) Abnormally high neuronal density in the schizophrenic cortex – a morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 52: 805–818.
[11]
Selemon LD, Rajkowska G, Goldman-Rakic PS (1998) Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: Application of a three-dimensional, stereologic counting method. J Comp Neurol 392: 402–412.
[12]
Rajkowska G, Selemon LD, Goldman-Rakic PS (1998) Neuronal and glial somal size in the prefrontal cortex – A postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 55: 215–224.
[13]
Pierri JN, Volk CLE, Auh S, Sampson A, Lewis DA (2001) Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry 58: 466–473.
[14]
Pierri JN, Volk CLE, Auh S, Sampson A, Lewis DA (2003) Somal size of prefrontal cortical pyramidal neurons in schizophrenia: Differential effects across neuronal subpopulations. Biol Psychiatry 54: 111–120.
[15]
Chana G, Landau S, Beasley C, Everall IP, Cotter D (2003) Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: Evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry 53: 1086–1098.
[16]
Sweet RA, Bergen SE, Sun ZX, Sampson AR, Pierri JN, et al. (2004) Pyramidal cell size reduction in schizophrenia: Evidence for involvement of auditory feedforward circuits. Biol Psychiatry 55: 1128–1137.
[17]
Pennington K, Dicker P, Hudson L, Cotter DR (2008) Evidence for reduced neuronal somal size within the insular cortex in schizophrenia, but not in affective disorders. Schizophr Res 106: 164–171.
[18]
Behrens MM, Ali SS, Dao DN, Lucero J, Shekhtman G, et al. (2007) Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 318: 1645–1647.
[19]
Cerqueira JJ, Pego JM, Taipa R, Bessa J, Almeida OFX, et al. (2005) Morphological correlates of corticosteroid-induced changes in prefrontal cortex-dependent behaviors. J Neurosci 25: 7792–7800.
[20]
Kalus P, Muller TJ, Zuschratter W, Senitz D (2000) The dendritic architecture of prefrontal pyramidal neurons in schizophrenia patients. Neuroreport 11: 3621–3625.
[21]
Broadbelt K, Byne W, Jones LB (2002) Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenia medial prefrontal cortex. Schizophr Res 58: 75–81.
[22]
Black JE, Kodish IM, Grossman AW, Klintsova AY, Orlovskaya D, et al. (2004) Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. Am J Psychiatry 161: 742–744.
[23]
Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, et al. (1998) Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry 65: 446–453.
[24]
Glantz LA, Lewis DA (2000) Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 57: 65–73.
[25]
Sweet RA, Henteneff RA, Zhang W, Sampson AR, Lewis DA (2009) Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. Neuropsychopharmacology 34: 374–389.
[26]
Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6: 312–324.
[27]
DeFelipe J, Farinas I (1992) The pyramidal neurons of the cerebral cortex: morphological and chemical characteristic of the synaptic inputs. Prog Neurobiol 39: 563–607.
[28]
Hirsch SR, Das I, Garey LJ, De Belleroche J (1997) A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction. Pharmacol Biochem Behav 56: 797–802.
[29]
Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA (2005) Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 29: 846–858.
[30]
Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF (2006) Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 81: 47–63.
[31]
Hashimoto T, Arion D, Maldonado-Aviles JG, Morris HM, Volk DW, et al. (2008) Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 13: 147–161.
[32]
Thompson M, Weickert CS, Wyatt E, Webster MJ (2009) Decreased glutamic acid decarboxylase(67) mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders. J Psychiatric Res 43: 970–977.
[33]
Gonzalez-Burgos G, Hashimoto T, Lewis DA (2010) Alterations of cortical GABA neurons and network oscillations in schizophrenia. Curr Psychiatry Rep 12: 335–344.
[34]
Beasley CL, Reynolds GP (1997) Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 24: 349–355.
[35]
Reynolds GP, Beasley CL (2001) GABAergic neuronal subtypes in the human frontal cortex – development and deficits in schizophrenia. J Chem Neu 22: 95–100.
[36]
Reynolds GP, Beasley CL, Zhang ZJ (2002) Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons. J Neural Transm 109: 881–889.
[37]
Hashimoto T, Bazmi HH, Mirnics K, Wu Q, Sampson AR, et al. (2008) Conserved regional patters of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry 165: 479–489.
[38]
Sakai T, Oshima A, Nozaki Y, Ida I, Haga C, et al. (2008) Changes in density of calcium-binding-protein-immunoreactice GABAergic neurons in prefrontal cortex in schizophrenia and bipolar disorder. Neuropathology 28: 143–150.
[39]
Mellios N, Huang H-S, Baker SP, Galdzicka M, Ginns E, et al. (2009) Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol Psychiatry 65: 1006–1014.
[40]
Bitanihirwe BKY, Lim MP, Kelley JF, Kaneko T, Woo TUW (2009) Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia. BMC Psychiatry 9: 71.
[41]
Fung SJ, Webster MJ, Sivagnanasundaram S, Duncan C, Elashoff M, et al. (2010) Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry 167: 1479–1488.
[42]
Morris HM, Hashimoto T, Lewis DA (2008) Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cerebral Cortex 18: 1575–1587.
[43]
Catts VS, Catts SV (2010) Psychotomimetic effects of PCP, LSD, and ecstasy: Pharmacological models of schizophrenia? In: Sachdev PS, Keshaven MS, editors. Secondary Schizophrenia. Cambridge UK: Cambridge University Press. pp. 141–168.
[44]
Buttner N, Bhattacharyya S, Walsh J, Benes FM (2007) DNA fragmentation is increased in non-GABAergic neurons in bipolar disorder but not in schizophrenia. Schizophr Res 93: 33–41.
[45]
Benes FM, Lim B, Subburaju S (2009) Site-specific regulation of cell cycle and DNA repair in post-mitotic GABA cells in schizophrenia versus bipolars. Proc Natl Acad Sci U S A 106: 11731–11736.
[46]
Benes FM (2010) Relationship of GAD67 regulation to cell cycle and DNA repair in GABA neurons in the adult hippocampus. Cell Cycle 9: 625–627.
[47]
Jin Z, El-Deiry WS (2005) Overview of cell death signaling pathways. Cancer Biol and Ther 4: 139–163.
[48]
Higgs B, Elashoff M, Richman S, Barci B (2006) An online database for brain disease research. BMC Genomics 7: 70.
[49]
Kelly K, Manos E, Jensen G, Nadauld L, Jones DA (2000) APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death. Cancer Res 60: 1021–1027.
[50]
Harrison PJ, Heath PR, Eastwood SL, Burnet PW, McDonald B, et al. (1995) The relative importance of premortem acidosis and postmortem interval form human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins. Neurosci Lett 200: 151–154.
[51]
Kingsbury AE, Foster OJ, Nisbet AP, Carins N, Bray L, et al. (1995) Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res 28: 311–318.
[52]
Djerbi M, Darreh-Shori T, Zhivotovsky B, Grandien A (2001) Characterization of the human FLICE-inhibitory protein locus and comparison of the anti-apoptotic activity of four different FLIP isoforms. Scand J Immunol 54: 180–189.
[53]
Thangarajh MT, Masterman T, Hillert J, Moerk S, Jonsson R (2007) A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis. Scand J Immunol 65: 92–98.
[54]
Mhawech-Fauceglia P, Kaya G, Sauter G, McKee T, Donze O, et al. (2006) The source of APRIL up-regulation in human solid tumor lesions. J Leukocyte Biol 80: 697–704.
[55]
Mackay F, Ambrose C (2003) The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev 14: 311–324.
[56]
Montgomery RI, Warner MS, Lum BJ, Spear PG (1996) Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87: 427–436.
[57]
Reich A, Spering C, Schulz JB (2008) Death receptor FAS (CD95) signaling in the central nervous system: tuning neuroplasticity? Trend Neurosci 31: 478–486.
[58]
Chang DW, Xing Z, Pan Y, Algeciras-Schiminch A, Barnhart BC, et al. (2002) c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 21: 3704–3714.
[59]
Dallas PB, Gottardo NG, Firth MJ, Beesley AH, Hoffmann K, et al. (2005) Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR – how well do they correlate? BMC Genomics 6: 59.
[60]
McKernan DP, Dinan TG, Cryan JF (2009) “Killing the Blues”: A role for cellular suicide (apoptosis) in depression and the antidepressant response? Prog Neurobiol 88: 246–263.
[61]
Mexal S, Frank M, Berger R, Adams CE, Ross RG, et al. (2005) Differential modulation of gene expression in the NMDA postsynaptic density of schizophrenia and control smokers. Mol Brain Res 139: 317–332.
[62]
Beasley CL, Zhang ZJ, Patten I, Reynolds GP (2002) Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry 52: 708–715.
[63]
Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, et al. (2005) Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brain. Biol Psychiatry 3: 252–260.
[64]
Weickert CS, Straub RE, McClintock BW, Matsumoto M, Hashimoto R, et al. (2004) Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Am J Psychiatry 61: 544–555.
[65]
Kristiansen LV, Beneyto M, Haroutunian V, Meador-Woodruff JH (2006) Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry 11: 737–747.
[66]
Corsini NS, Sancho-Martinez I, Laudenklos S, Glagow D, Kumar S, et al. (2009) The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell 5: 178–190.
[67]
Zuliani CS, Kleber S, Klussmann S, Wenger T, Kenzelmann M, et al. (2006) Control of neuronal branching by the death receptor CD95 (Fas/Apo-1). Cell Death Differ 13: 31–40.
[68]
Conti B, Tabarean I, Sanchez-Alavez M, Davis C, Brownell S, et al. (2008) Cytokine receptors in the brain. In: Phelps C, Korneva EA, editors. Cytokines and the Brain. Oxford UK: Elsevier. pp. 21–38.
[69]
Behrens MM, Ali SS, Dugan LL (2008) Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci 28: 13957–13966.
[70]
Henderson LM, Chappell JB, Jones OTG (1998) Internal pH changes associated with the activity of NADPH oxidase of human neutrophils. Biochem J 251: 563–567.
[71]
Mulkey DK, Henderson RA III, Ritucci NA, Putnam RW, Dean JB (2004) Oxidative stress decreases pHi and Na+/H+ exchange and increases excitability of solitary complex neurons from rat brain slices. Am J Physiol Cell Physiol 286: C940–C951.
[72]
Feng J, Yan Z, Ferreira A, Tomizawa K, Liauw JA, et al. (2000) Spinophilin regulates the formation and function of dendritic spines. Proc Natl Acad Sci U S A 97: 9287–9292.
[73]
Weickert CS, Sheedy D, Rothmond DA, Dedova I, Fung S, et al. (2010) Selection of reference gene expression in a schizophrenia brain cohort. Aust N Z J Psychiatry 44: 59–70.
[74]
Franck P, Petitipain N, Cherlet M, Dardennes M, Maachi F, et al. (1996) Measurement of intracellular pH in cultured cells by flow cytometry with BCECF-AM. J Biotechnol 46: 187–195.
[75]
Field A (2005) Discovering Statistics Using SPSS. London, UK: Sage Publications. pp. 32–33, 302–303, 531–532.
[76]
Lavrik I, Golks A, Krammer PH (2005) Death receptor signaling. J Cell Sci 118: 265–267.
